Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery

ConditionsCoronary Artery Disease Multivessel Coronary Artery Disease

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorCardiology Research UBC

About this trial

The study objective is to compare standard CABG to a hybrid revascularization strategy (RA-MIDCAB + PCI) in patients who have multi-vessel CAD and an indication for surgery, but who have a slightly higher risk of post-operative complications.

Eligibility criteria

Qualifiers

Multi-vessel CAD with an indication for revascularization,

Presence of at least 1 risk factor for increased risk of post-operative death or major complication,

Any patient Age > 80, OR

Any patient with eGFR (Glomerular Filtration Rate) < 50, OR

Disqualifiers

Significant left main coronary artery disease,

Ejection fraction < 30%,

Patients with GFR < 30,

Patients unable to take dual anti-platelet agents due to high bleeding risk,

Trial design

Treatments tested in this trial

Coronary Artery Bypass Graft
Robotically-assisted minimally-invasive direct coronary artery bypass
Percutaneous Coronary Intervention

Treatment groups

80 Participants

are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

Cardiology Research UBC

Lead sponsor

Source ClinicalTrials.gov